Abstract
Proteomics can generate important applications for cancer research and cancer care by (1) profiling tumor specimens for diagnosis and for prognosis with particular therapies; (2) discovering and validating circulating serum or plasma proteins, including auto-antibodies, as biomarkers for early diagnosis; and (3) applying such biomarkers to monitoring of patients for responses to treatment and recurrence of tumors. Proteins are much closer to the pathophysiologic changes and molecular targets for drugs than are mRNAs; changes in mRNAs and corresponding proteins often are not highly correlated. Plasma proteomics must overcome the challenges of enormous complexity, huge dynamic range, in vivo and ex vivo degradation, lack of standardized procedures for sample handling and analysis, inherently incomplete sampling by mass spectrometry, and redundancy, incompleteness, and evolution of databases. Rapidly emerging advances in fractionation of complex protein mixtures, identification and quantitation of peptides and proteins, and quality of curated databases of proteins will accelerate the development of biomarker profiles for specific cancers and cancer mechanisms. The construction of a knowledge base of circulating proteins from the HUPO Plasma Proteome Project will be highlighted. Reported findings for various cancers will be reviewed. [Supported by MTTC grant 687 and NCI contract DA021519.]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
